Section/topic #Checklist item Reported on page # TITLE Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality – A systematic review and analysis of trial design considerationsTitle 1Identify the report as a systematic review, meta-analysis, or both. 1ABSTRACT Structured summary 2Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. 2Registration number not availableINTRODUCTION Rationale 3Describe the rationale for the review in the context of what is already known. 3,4Objectives 4Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 3METHODS Protocol and registration 5Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. 4,11Eligibility criteria 6Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. 4Information sources 7Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 4Search 8Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 4Study selection 9State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). 4Data collection process 10Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 4Data items 11List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 4Risk of bias in individual studies 12Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. N/ASummary measures 13State the principal summary measures (e.g., risk ratio, difference in means). N/ASynthesis of results 14Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. N/APage 1 of 2 Section/topic #Checklist item Reported on page # Risk of bias across studies 15Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). N/AAdditional analyses 16Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. N/ARESULTS Study selection 17Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 5Study characteristics 18For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 5Risk of bias within studies 19Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). N/AResults of individual studies 20For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 5,6,7Synthesis of results 21Present results of each meta-analysis done, including confidence intervals and measures of consistency. N/ARisk of bias across studies 22Present results of any assessment of risk of bias across studies (see Item 15). N/AAdditional analysis 23Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). N/ADISCUSSION Summary of evidence 24Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). 8,9,10Limitations 25Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). 10Conclusions 26Provide a general interpretation of the results in the context of other evidence, and implications for future research. 11FUNDING Funding 27Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 11From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit: www.prisma-statement.org. Page 2 of 2 PRISMA 2009 Checklist/9j/4AAQSkZJRgABAgEAkACQAAD/4gxYSUNDX1BST0ZJTEUAAQEAAAxITGlubwIQAABtbnRyUkdC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Normal038074600Microsoft Office Word03810falseTitle1Microsoft Word - PRISMA 2009 Checklist.docUniversity of Oxfordfalse5397falsefalse16.0000Microsoft Word - PRISMA 2009 Checklist.docmocampoSimango, Samuel [ssimango@sun.ac.za]22019-08-29T09:37:00Z2019-08-29T09:37:00Z